Group 1 - The company announced changes to its registered capital, cancellation of the supervisory board, and amendments to its articles of association [1][3][21] - The company issued 5.25 million convertible bonds with a total value of 525 million yuan, which can be converted into A-shares starting from June 7, 2021 [1][2] - As of December 31, 2024, a total of 139,000 yuan of convertible bonds have been converted into 16,623 shares, increasing the total share capital from 721,227,382 shares to 721,244,005 shares [2] Group 2 - The supervisory board will be abolished, and its powers will be transferred to the audit committee of the board of directors, in accordance with relevant laws and regulations [3][21] - The amendments to the articles of association require approval from the shareholders' meeting, and the management is authorized to handle related business registration changes [4][21] Group 3 - The company held its fourth board meeting on September 22, 2025, where it approved the nomination of candidates for the fifth board of directors [8][33] - The fifth board will consist of 7 directors, including 3 non-independent directors, 3 independent directors, and 1 employee representative [33][34] - The company plans to hold a second extraordinary shareholders' meeting on October 10, 2025, to vote on the board nominations and other matters [47][50] Group 4 - The company aims to revise its governance structure to better protect the rights of investors, especially minority shareholders, and promote sustainable development [25][69] - The revised governance documents include rules for external investment management, shareholder meetings, independent director work, related party transactions, and fundraising management [69][70]

New Stock Issuance - Guangdong JianKe issued new shares at a price of 6.56 on August 1, 2025[1] - ShenKe Co., Ltd. has a tender offer period from July 29 to August 27, 2025[1] - ST Kelly's tender offer period is from July 17 to August 15, 2025[1] Market Alerts - ST Zitian reported significant abnormal fluctuations on July 21, 2025[1] - ST Suwu experienced abnormal fluctuations on July 30, 2025[1] - ST Xizang Tianlu reported significant abnormal fluctuations on August 1, 2025[1] Other Notable Announcements - Huaneng Electric's announcement was made on August 1, 2025, regarding its stock code 603063[1] - ST Sai Long's announcement was made on August 1, 2025, with stock code 002898[1] - ST Green Kang's announcement was made on July 31, 2025, with stock code 002868[1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603669 证券简称：灵康药业 公告编号：2025-053 灵康药业集团股份有限公司 2025年第一次临时股东大会决议公告 一、会议召开和出席情况 (一)股东大会召开的时间：2025年7月30日 (二)股东大会召开的地点：浙江省杭州市上城区民心路100号万银国际大厦27层，浙江灵康药业有限公 司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，由公司董事长陶灵萍女士主持。本次会议的召集、召开、表决方式符合有 关法律、行政法规、部门规章和《公司章程》的有关规定。本次股东大会的召开合法、有效。上海东方 华银律师事务所律师出席了本次会议，并就股东大会召集和召开程序的合法性出具了法律意见书。 (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事 ...

证券代码：603669 证券简称：灵康药业 公告编号：2025-054 债券代码：113610 证券简称：灵康转债 ? 修正后的转股价格：6.50 元/股 ? "灵康转债"本次转股价格修正实施日期：2025 年 8 月 1 日 灵康药业集团股份有限公司 关于向下修正"灵康转债"转股价格暨转股停复牌的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 证券停复牌情况：适用 因"灵康转债"按照转股价格向下修正条款调整转股价格，本公司的相关证券停 复牌情况如下： 证券代码 证券简称 停复牌类型 停牌起始日 停牌期间 停牌终止日 复牌日 ? 修正前的转股价格：8.00 元/股 ? "灵康转债"2025 年 7 月 31 日停止转股，2025 年 8 月 1 日起恢复转股 一、可转换公司债券的基本情况 （一）经中国证券监督管理委员会证监许可[2020]2640 号文核准，灵康药业 集团股份有限公司（以下简称"灵康药业"或"本公司"）于 2020 年 12 月 1 日公 开发行了 525 万张可转换公司债券，每张面 ...

Group 1 - The core viewpoint of the article discusses recent developments in the Chinese stock market, particularly focusing on new stock listings and convertible bonds [1] - The new stock "Youli Intelligent" on the Beijing Stock Exchange has a threshold of 6.47 million [1] - The "Lincang Convertible Bond" is undergoing a down adjustment [1] - The "Gansu Energy Chemical" has resumed production at its Wangjiashan Coal Mine, well number one [1] - The "Aofei Convertible Bond" will not be forcibly redeemed [1] - "Dongjie Intelligent" is undergoing changes in its controlling shareholder's upper-level equity structure, which may lead to a change in the actual controller [1] - The "Xianle Convertible Bond," "Shengxun Convertible Bond," and "Jingrui Convertible Bond 2" will not undergo down adjustments [1] - "Dingjia Precision" has been listed as a new stock on the Beijing Stock Exchange [1]

（文章来源：证券日报） 证券日报网讯 7月30日晚间，灵康药业发布公告称，公司2025年第一次临时股东大会于2025年7月30日 召开，审议通过了《关于向下修正"灵康转债"转股价格的议案》。 ...

Group 1 - The company is holding its first extraordinary general meeting of shareholders in 2025 on July 30 at 14:30 in Hangzhou, Zhejiang [1] - The agenda includes signing in, reviewing proposals, voting, announcing results, and waiting for online voting results [1][2] - The board of directors is proposing to lower the conversion price of "Lingkang Convertible Bonds" to support long-term stable development and optimize the capital structure [3] Group 2 - The board seeks authorization from the shareholders to handle matters related to the adjustment of the conversion price, including determining the new price and effective date [3] - The authorization is valid from the date of approval at the shareholders' meeting until the completion of the related work [3]

Group 1 - The China Securities Convertible Bond Index opened nearly flat [1] - Huahong Convertible Bond rose over 11% [1] - Jintong Convertible Bond increased by more than 6% [1] - Lingkang Convertible Bond saw a rise of over 3% [1] Group 2 - Saili Convertible Bond declined by more than 6% [1] - Beilu Convertible Bond, Feilu Convertible Bond, Guanda Convertible Bond, and Yong'an Convertible Bond each fell by over 3% [1]

Core Viewpoint - The board of directors of Lingkang Pharmaceutical Group Co., Ltd. proposes to lower the conversion price of "Lingkang Convertible Bonds" due to the stock price being below 85% of the current conversion price for at least 15 out of the last 30 trading days [1][4]. Summary by Sections 1. Basic Information of Convertible Bonds - Lingkang Pharmaceutical issued 5.25 million convertible bonds on December 1, 2020, with a face value of 100 yuan each, totaling 525 million yuan [2]. - The bonds are traded under the name "Lingkang Convertible Bonds" with the code "113610" [2]. 2. Conversion Price Adjustment Terms and Trigger Conditions - The conversion price can be adjusted if the stock price is below the current conversion price for at least 15 out of 30 consecutive trading days [3]. - The initial conversion price was set at 8.81 yuan per share, with the latest adjustment bringing it down to 8.00 yuan per share [2]. 3. Procedures for Price Adjustment Proposal - The board meeting on July 14, 2025, approved the proposal to lower the conversion price and will submit it to the shareholders' meeting for approval [4]. - The adjusted conversion price must not be lower than the higher of the average stock price over the 20 trading days prior to the shareholders' meeting and the previous trading day's average [5].

Group 1 - The board of directors of Lingkang Pharmaceutical Group Co., Ltd. held its 33rd meeting on July 14, 2025, to discuss the downward adjustment of the conversion price of "Lingkang Convertible Bonds" [1][2] - The board proposed to authorize the board to handle matters related to the adjustment of the conversion price, including determining the new conversion price and effective date [1] - The meeting was attended by all 7 directors, and the resolution was deemed legal and effective [1][2] Group 2 - The proposal to adjust the conversion price requires approval at the company's first extraordinary general meeting of shareholders in 2025 [2]